Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Comparative Effectiveness Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/cer-2016-0042PMID 27854129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes.

  2016cited by this paper
• Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

  2016cited by this paper
• Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development

  2016cited by this paper
• Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

  2016cited by this paper
• Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

  2015cited by this paper
• Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)

  2015cited by this paper
• Effectiveness of sofosbuvir‐based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans

  2015cited by this paper
• Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.

  2015cited by this paper
• The PRECIS-2 tool: designing trials that are fit for purpose

  2015cited by this paper
• Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir

  2015cited by this paper
• Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort

  2015cited by this paper
• Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

  2015cited by this paper
• Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis

  2015cited by this paper
• Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

  2015cited by this paper
• Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

  2015cited by this paper
• Trends in breakthrough therapy designation

  2015cited by this paper
• Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

  2015cited by this paper
• P0847 : Malachite-II: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1

  2015cited by this paper
• A multi-journal partnership to highlight joint first-authors of manuscripts.

  2015cited by this paper
• P0826 : Effectiveness of simeprevir (SMV)-containing regimens among patients with chronic hepatitis C virus (HCV) in various us practice settings: Interim analysis of the sonet study

  2015cited by this paper
• P0849 : Real-world effectiveness of sofosbuvir (SOF), telaprevir, and boceprevir (T, B) based therapy for hepatitis C virus (HCV): An analysis in a large integrated health care system

  2015cited by this paper
• O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience

  2015cited by this paper
• LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

  2015cited by this paper
• LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

  2015cited by this paper
• Tu1014 Single-Center Real-World Experience of Sofosbuvir Plus Simeprevir for 12 Weeks for Genotype 1 Chronic Hepatitis C With Advanced Fibrosis

  2015cited by this paper
• 1011 Final Evaluation of 955 HCV Patients Treated With 12 Week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

  2015cited by this paper
• 367 Effectiveness of Sofosbuvir-Based Hepatitis C (HCV) Antiviral Regimens in a Large U.S. Veteran Cohort

  2015cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2015.

  2015cited by this paper
• Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

  2015cited by this paper
• Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.

  2015cited by this paper
• Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.

  2015cited by this paper
• First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort

  2015cited by this paper
• The year's new drugs & biologics, 2014: Part I.

  2015cited by this paper
• Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

  2015cited by this paper
• Difficult‐to‐cure populations with chronic hepatitis c: Vanishing in the direct‐acting antiviral era?

  2015cited by this paper
• P1197 REAL-WORLD TREATMENT WITH FIRST GENERATION TRIPLE THERAPY FOR HCV-GT1 DIFFICULT-TO-TREAT PATIENTS: FINAL RESULTS OF AN OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED LIVER DISEASE AND NONRESPONSE

  2014cited by this paper
• Factors influencing adherence in Hepatitis-C infected patients: a systematic review

  2014cited by this paper
• Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

  2014cited by this paper
• Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

  2014cited by this paper
• Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

  2014cited by this paper
• Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Failing FXR expression in the liver links aging to hepatic steatosis.

  2014cited by this paper
• Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

  2014cited by this paper
• Global epidemiology and genotype distribution of the hepatitis C virus infection.

  2014cited by this paper
• New hepatitis C therapies: the toolbox, strategies, and challenges.

  2014cited by this paper
• HCV transmission by hepatic exosomes establishes a productive infection.

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives

  2014cited by this paper
• Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments

  2014cited by this paper
• Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

  2014cited by this paper
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

  2014cited by this paper
• Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

  2014cited by this paper
• Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.

  2014cited by this paper
• Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting

  2014cited by this paper
• Epidemiology and natural history of hepatitis C virus infection.

  2014cited by this paper
• Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

  2014cited by this paper
• Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.

  2014cited by this paper
• Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

  2014cited by this paper
• Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

  2014cited by this paper
• Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.

  2014cited by this paper
• Treatment of hepatitis C, then, now and tomorrow

  2014cited by this paper
• Su1069 SVR Rates With Telaprevir and Boceprevir in US Clinical Practice

  2014cited by this paper
• P1200 EFFECTIVENESS OF TRIPLE THERAPY WITH BOCEPREVIR OR TELAPREVIR IN A MULTICENTRE CLINICAL PRACTICE COHORT OF HCV TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED HEPATIC FIBROSIS. SVR-12W AFTER TREATMENT

  2014cited by this paper
• Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

  2014cited by this paper
• Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

  2014cited by this paper
• ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

  2014cited by this paper
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

  2014cited by this paper
• Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

  2014cited by this paper
• ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

  2014cited by this paper
• Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

  2013cited by this paper
• Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

  2013cited by this paper
• Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

  2013cited by this paper
• 845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY

  2013cited by this paper
• Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

  2013cited by this paper
• An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013cited by this paper
• Emerging treatments for hepatitis C

  2013cited by this paper
• Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta‐analysis

  2013cited by this paper
• Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study

  2013cited by this paper
• The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries

  2013cited by this paper
• Current and future therapies for hepatitis C virus infection.

  2013cited by this paper
• Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

  2013cited by this paper
• Sa1044 Telaprevir: A Real World Experience

  2013cited by this paper
• Sa1058 Boceprevir: A Real World Experience

  2013cited by this paper
• Hepatitis C: epidemiology, diagnosis, natural history and therapy.

  2012cited by this paper
• Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.

  2012cited by this paper
• Natural history of acute and chronic hepatitis C.

  2012cited by this paper
• Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection

  2012cited by this paper
• Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

  2012cited by this paper
• Boceprevir: a protease inhibitor for the treatment of hepatitis C.

  2012cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Telaprevir for retreatment of HCV infection.

  2011cited by this paper
• Determination of the burden of hepatitis C virus infection in Ireland

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Response-guided telaprevir combination treatment for hepatitis C virus infection.

  2011cited by this paper

• Who benefits? Uncovering hidden heterogeneity of treatment effects in adaptive trials using Bayesian methods: a systematic review

  2025cites this paper
• Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study.

  2024cites this paper
• Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in

  2022cites this paper
• Heterogeneity in treatment effects across diverse populations

  2021cites this paper
• No inexplicable disagreements between real-world-data based non-randomized controlled studies and randomized controlled trials were found.

  2020cites this paper
• Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis

  2020cites this paper
• Natural Language Processing for Mimicking Clinical Trial Recruitment in Critical Care: A Semi-Automated Simulation Based on the LeoPARDS Trial

  2019cites this paper
• Designing pragmatic trials-what can we learn from lessons learned?

  2017cites this paper